A newer therapy that acts like a Trojan horse to attack bacteria should be reserved for patients with certain treatment-refractory lung infections, according to updated nontuberculous mycobacterial (NTM) pulmonary disease guidelines released by the IDSA, the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the European Society of Clinical Microbiology and Infectious Disease (ESCMID).
As the COVID-19 pandemic continues to challenge health care professionals across the nation, the IDSA and the CDC have partnered to build connections across health care disciplines and to provide access to the latest information on fighting the disease that has ended the lives of more than 100,000 Americans and affected even more.
Reports that the White House may be considering significantly reducing the role of the Centers for Disease Control and Prevention are deeply concerning. America remains at the center of a global pandemic and needs well-established, credible scientists—not political appointees—informing public health decisions.
The rules in the Patient Protection and Affordable Care Act barring discrimination by health insurers and providers against transgender people offered essential protections for a population facing significant barriers to health care.
As strict stay-at-home orders are suspended in states across the country and mass calls for racial justice continue to bring large numbers of people together, individual protective measures as well as responsive public policies and resources will be paramount to controlling the spread of COVID-19.
As the numbers of physicians specializing in infectious diseases continues to fall short of need, nearly two-thirds of Americans live in areas with little or no access to an infectious diseases specialist, according to a study published online today in the Annals of Internal Medicine.
The incomprehensible death of George Floyd has left our country grieving and demands attention to the environment of disparities, inequities and structural racism in which it occurred. As infectious diseases and HIV health care providers, we stand against discrimination in any form.
Meeting requested to address questions, inform planning for use of remdesivir, the only FDA-authorized drug for COVID-19 treatment.
H.R.6800, the Health Heroes Act, includes policies and investments that would bolster the federal response to COVID-19, increase testing capacity and availability of medical supplies and address the disparate impact of COVID-19 on vulnerable populations.
The U.S. Department of Health and Human Services decision allowing state health departments to distribute limited supplies of remdesivir to treat COVID-19 where they are needed will support fair and equitable access to the drug.
Strong and specific federal guidance is critical to protecting our country, our communities, our health and our lives in the face of the still escalating impacts of COVID-19 across the United States.
With FDA emergency authorization of remdesivir to treat COVID-19, the Infectious Diseases Society of America and its HIV Medicine Association are calling on Vice President Mike Pence and other administration officials to provide public transparency in the process for determining how and where the medication is distributed